Evidence map›Paper›PMID 35012600›Full record

ArticleOrphanet journal of rare diseases2022

Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica's experience.

R Badilla-Porras, A Echeverri-McCandless, J M Weimer, A Ulate-Campos, A Soto-Rodríguez, A Gutiérrez-Mata, L Hernández-Con, S Bogantes-Ledezma, A Balmaceda-Meza, J Brudvig and 1 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Rare adult neuronal ceroid lipofuscinosis associated withWorld journal of clinical cases · 2023
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

R Badilla-PorrasClinical Genetic and Metabolism Department, National Children's Hospital, CCSS, San José, Costa Rica.
A Echeverri-McCandlessResearch Unit, Hospital San Juan de Dios, CCSS, San José, Costa Rica. aecheverri@clinicaviasanjuan.com.ORCID 0000-0001-6846-0183
J M WeimerPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.
A Ulate-CamposNeurology Department, National Children's Hospital, CCSS, San José, Costa Rica.
A Soto-RodríguezResearch Unit, Hospital San Juan de Dios, CCSS, San José, Costa Rica.
A Gutiérrez-MataNeurology Department, National Children's Hospital, CCSS, San José, Costa Rica.
L Hernández-ConNeurology Department, National Children's Hospital, CCSS, San José, Costa Rica.
S Bogantes-LedezmaNeurology Department, National Children's Hospital, CCSS, San José, Costa Rica.
A Balmaceda-MezaCENDEISSS, CCSS, San José, Costa Rica.
J BrudvigPediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA.
A Sanabria-CastroResearch Unit, Hospital San Juan de Dios, CCSS, San José, Costa Rica.
Hospital Nacional de Niños · CRSanford Research · USCosta Rican Department of Social Security · CRHospital San Juan de Dios · CLUniversidad de Costa Rica · CR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population.

objectiveTo describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children's Hospital in Costa Rica and to characterize via molecular testing their causative mutations.

methodsDNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants' sociodemographic and clinical characteristics were also obtained from their medical records.

resultsNine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens.

conclusionsThis investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies.

Indexed as

Neuronal Ceroid-LipofuscinosesChildCosta RicaHumansMembrane ProteinsMutationPedigreeCLN6 protein, humanMembrane ProteinsBatten diseaseCNL6Lysosomal storage diseaseNeuronal ceroid lipofuscinosisVariant late infantile NCLvLINCL

Identifiers

PMID35012600
PMCPMC8751374
OpenAlexW4205186801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.